content

Amarin has earned a much-needed triumph internationally after faltering in the crucial US market. Vazkepa has been approved by the National Institute for Health...

Teva can rest easy knowing that it does have a long runway free of generics—at least from two major challengers—as it focuses on the...

Despite a high-profile FDA denial, FibroGen and its collaborators have been able to expand into new markets outside of the United States with Evrenzo,...

As many Americans face difficult financial decisions thanks to inflation, a new study verifies what many have feared for years: drug prices are significantly...

Bluebird bio has persuaded an expert committee that the benefits of its gene therapy possibility, eli-cel, exceed the risks, at least in certain patients,...

Alnylam has outlined their strategy for delivering siRNA to the central nervous system and other organs outside of the liver. The RNA specialist detailed...

Merck & Co. was not at all a prominent oncology player before the advent of Keytruda. The New Jersey drugmaker wants to consolidate its supremacy...